Von Hippel-Lindau Tumor Suppressor (VHL) Antikörper

Antigen: Von Hippel-Lindau Tumor Suppressor (VHL)

Synonyme: RCA1, VHL1, HRCA1, Vhlh, BcDNA:RH61560, VHL, d-VHL, dVHL, dmVHL, Dmel\CG13221, CG13221, rca1, vhl1, hrca1, zgc:158722, DKFZp469K2019

Klonalität: Polyklonal

Wirt: Kaninchen

Applikation: Western Blot (WB)

Produktnummer: ABIN123801

Produktbeschreibung

Weitere Bezeichnung: von Hippel-Lindau

Format: Liquid

Beschreibung: Von Hippel-Lindau (VHL) disease is a hereditary cancer with a predilection for the central nervous system and retina. The von Hippel-Lindau tumor suppressor gene is mutated in families with von Hippel-Lindau disease and encodes a protein (VHL) of 213 amino acids with an acidic pentapeptide motif in the N-terminus. Mutations in the VHL gene result in constitutive expression of many hypoxi-induced genes, at least in part because of increases in the cellular level of hypoxia-inducible transcription factor HIF-1 alpha. VHL protein binds to elongin B, elongin C, and Cul2 to form a stable complex that targets hypoxia inducibal factors (HIFs) for degradation and transcriptional regulation. In addition, VHL protein has also been shown to interact with specific protein kinase C isoforms, histone deacetylases and HIF-1 inhibitor (FIH-1). alpha-VHL is an affinity-purified rabbit polyclonal antibody raised against the recombinant VHL protein.

Spezifität: Alpha-VHL reacts with the VHL protein in HeLa nuclear extract by Western blotting.

Anwendungen

Applikationshinweise: Recommended dilution range for Western blot analysis: 1:200 - 1:1000.

Lagerung: store at -80 °C, avoid freeze/thaw cycles. Shipped on dry ice. Shelf Life: 12 months.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Duan, Humphrey, Chen et al.: "Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 14, pp. 6459-63, 1995 (PubMed).

Duan, Pause, Burgess et al.: "Inhibition of transcription elongation by the VHL tumor suppressor protein." in: Science (New York, N.Y.), Vol. 269, Issue 5229, pp. 1402-6, 1995 (PubMed).

Linehan, Lerman, Zbar: "Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer." in: JAMA : the journal of the American Medical Association, Vol. 273, Issue 7, pp. 564-70, 1995 (PubMed).

Latif, Tory, Gnarra et al.: "Identification of the von Hippel-Lindau disease tumor suppressor gene." in: Science (New York, N.Y.), Vol. 260, Issue 5112, pp. 1317-20, 1993 (PubMed).

Pal, Claffey, Dvorak et al.: "The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways." in: The Journal of biological chemistry, Vol. 272, Issue 44, pp. 27509-12, 1997 (PubMed).

Iwai, Yamanaka, Kamura et al.: "Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, Issue 22, pp. 12436-41, 1999 (PubMed).

Kamura, Sato, Iwai et al.: "Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, Issue 19, pp. 10430-5, 2000 (PubMed).

Singh, Shields, Shields: "von Hippel-Lindau disease." in: Survey of ophthalmology, Vol. 46, Issue 2, pp. 117-42, 2001 (PubMed).

Mahon, Hirota, Semenza: "FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity." in: Genes & development, Vol. 15, Issue 20, pp. 2675-86, 2001 (PubMed).